These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 7997375

  • 1. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB, Bartenstein P, Schober O, Oberwittler C, Lerch H, Masur H.
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [Abstract] [Full Text] [Related]

  • 2. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC.
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [Abstract] [Full Text] [Related]

  • 3. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W, Grundmann M, Huber G.
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S, Kämpfer I, Seese A, Schäfer A, Reuter M, Lössner J, Dietrich J, Wagner A, Knapp WH.
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [Abstract] [Full Text] [Related]

  • 8. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
    Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L, Podreka I, Brücke T.
    J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL.
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G, Gratz KF, Kolbe H, Meyer GJ, Dengler R, Knoop BO, Hundeshagen H.
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
    Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B, Müller C, Deecke L.
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
    [Abstract] [Full Text] [Related]

  • 16. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, Keske U, Hosten N, Mäurer J, Poewe W, Felix R.
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
    Schlösser R, Schlegel S, Hiemke C, Nickel O, Bockisch A, Rao ML, Hahn K.
    Psychiatry Res; 1997 Sep 29; 75(2):103-14. PubMed ID: 9351492
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.